FDA Approves Subcutaneous Opdivo Qvantig for Most Solid Tumor Indications
FRIDAY, Jan. 3, 2025 -- The U.S. Food and Drug Administration has approved Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) injection for subcutaneous use for most previously approved adult, solid tumor Opdivo (nivolumab) indications.
Opdivo Qvantig is a combination product of nivolumab coformulated with recombinant human hyaluronidase. This approval is for most previously approved adult, solid tumor Opdivo indications as monotherapy, monotherapy maintenance following completion of Opdivo plus Yervoy (ipilimumab) combination therapy, or in combination with chemotherapy or cabozantinib.
The approval is based on results from the phase 3 randomized, open-label CheckMate-67T trial, which demonstrated noninferiority for the coprimary end points of time-averaged concentration over 28 days and minimum concentration at a steady state of Opdivo Qvantig versus intravenous Opdivo. Additionally, the trial showed an overall response rate for Opdivo Qvantig of 24 percent versus 18 percent in the intravenous Opdivo arm.
"Over the last decade, Opdivo has evolved as an immunotherapy option used in many indications across tumor types," Adam Lenkowsky, executive vice president and chief commercialization officer at Bristol Myers Squibb, said in a statement. "With this new option, we look forward to further helping cancer patients with an administration method that gives them faster delivery."
Approval of subcutaneous Opdivo Qvantig was granted to Bristol Myers Squibb.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Read this next
One in 10 Undergoing Early Cancer Surgery Have New Persistent Opioid Use
MONDAY, Sept. 8, 2025 -- More than one in 10 veterans undergoing surgery for early-stage cancer develop new persistent opioid use, according to a study published online Sept. 8 in...
Healthy Plant-Based Diet May Cut Burden of Multimorbidity of Cancer and Cardiometabolic Diseases
MONDAY, Sept. 8, 2025 -- Among middle-aged and older adults, a healthy plant-based diet may reduce the burden of cancer and cardiometabolic diseases, according to a study...
Moderate-to-Severe TBI Linked to Malignant Brain Tumor Risk
FRIDAY, Sept. 5, 2025 -- A history of moderate-to-severe traumatic brain injury (TBI) is associated with an increased risk for developing malignant brain tumors, according to a...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.